GeneDx Holdings (WGS) Receivables - Net (2020 - 2026)

GeneDx Holdings (WGS) has reported Receivables - Net for 7 consecutive years, with $76.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net rose 67.3% year-over-year to $76.9 million; the TTM figure through Mar 2026 stood at $76.9 million (up 67.3% YoY), while the FY2025 annual figure was $74.4 million, up 97.64% from the prior year.
• Receivables - Net advanced to $76.9 million in Q1 2026 per WGS's latest filing, from $74.4 million in the prior quarter.
• Across five years, Receivables - Net topped out at $76.9 million in Q1 2026 and bottomed at $260000.0 in Q3 2024.
• Historically, Receivables - Net has averaged $37.2 million across 5 years, with a median of $37.6 million in 2022.
• Annual changes were most pronounced in 2024 — Receivables - Net slumped 99.19% — and 2025, when it jumped 23337.69%.
• GeneDx Holdings' Receivables - Net stood at $42.6 million in 2022, then slumped by 98.96% to $445000.0 in 2023, then jumped by 8355.96% to $37.6 million in 2024, then surged by 97.64% to $74.4 million in 2025, then gained by 3.44% to $76.9 million in 2026.
• Business Quant data shows WGS's Receivables - Net at $76.9 million in Q1 2026, $74.4 million in Q4 2025, and $60.9 million in Q3 2025.